Previously treated cases tested for RR-/MDR-TB (%) in Myanmar
Myanmar: Previously treated cases tested for RR-/MDR-TB was 94.0% in 2024. ◆ Volatile
Previously treated cases tested for RR-/MDR-TB in Myanmar, 2006–2024
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for previously treated cases tested for rr-/mdr-tb in Myanmar is 94.0%, measured in 2024.
Compared with earlier readings it is up 3.3% on the previous year and down 6.0% over ten years.
Over the whole period, previously treated cases tested for rr-/mdr-tb in Myanmar peaked at 100.0% in 2014 and was at its lowest, 3.8%, in 2012.
That places Myanmar 72nd out of 180 countries with data for 2024, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Previously treated cases tested for RR-/MDR-TB in Myanmar, year by year
| Year | Value | Change |
|---|---|---|
| 2006 | 9.4% | — |
| 2008 | 7.5% | -20.2% |
| 2009 | 9.9% | +32.0% |
| 2012 | 3.8% | -61.6% |
| 2013 | 70.0% | +1742.1% |
| 2014 | 100.0% | +42.9% |
| 2015 | 46.0% | -54.0% |
| 2016 | 63.0% | +37.0% |
| 2017 | 63.0% | +0.0% |
| 2018 | 84.0% | +33.3% |
| 2019 | 83.0% | -1.2% |
| 2020 | 87.0% | +4.8% |
| 2022 | 99.0% | +13.8% |
| 2023 | 91.0% | -8.1% |
| 2024 | 94.0% | +3.3% |
Myanmar compared with similar countries
- Myanmar's 94.0% is above the median for lower middle income countries, which is 90.0%, 1.0× the median. (47 countries reporting)
- Myanmar's 94.0% is above the median for East Asia & Pacific, which is 85.0%, 1.1× the median. (28 countries reporting)
Biggest year-on-year movements
Years where Previously treated cases tested for RR-/MDR-TB in Myanmar changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2013 | +1742.1% | 3.8% | 70.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 8.9% | 7.5% | 9.9% | 3 |
| 2010s | 64.1% | 3.8% | 100.0% | 8 |
| 2020s | 92.8% | 87.0% | 99.0% | 4 |
Countries ranked near Myanmar
More health data for Myanmar
- Un projection of annual infant deaths, annual growth rate -2.11 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.1576 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,398 deaths per 1,000 people (2090)
- Number of infants who die before age 1 2,973 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 7 (2025)
- Population ages 00-04, female, annual growth rate -0.759 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0387 units per person (2025)
- Population ages 00-04, male, annual growth rate -0.8351 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is previously treated cases tested for rr-/mdr-tb in Myanmar?
- Previously treated cases tested for rr-/mdr-tb in Myanmar was 94.0% in 2024, according to World Health Organization, Global Health Observatory.
- What is the highest previously treated cases tested for rr-/mdr-tb recorded in Myanmar?
- The highest recorded value was 100.0% in 2014.
- What is the lowest previously treated cases tested for rr-/mdr-tb recorded in Myanmar?
- The lowest recorded value was 3.8% in 2012.
- How does Myanmar rank for previously treated cases tested for rr-/mdr-tb?
- Myanmar ranks 72nd out of 180 countries with data for 2024.
- Is previously treated cases tested for rr-/mdr-tb rising or falling in Myanmar?
- Over the last ten years it is down 6.0%. The long-run trend across the full record is volatile.
- Where does this Myanmar data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Previously treated cases tested for RR-/MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 15 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).